Drug Metabolism in Diseases: Leveraging Drug Metabolism and Disposition in Precision Medicine and Therapeutic Development, Second Edition provides essential knowledge for pharmaceutical scientists and biologists to understand the interplay between diseases and physiological conditions, impacting drug metabolism and its implications in personalized treatment. Expanded with six new chapters since the first edition, this updated book covers the latest scientific findings. Other important points include the book’s comprehensive reference on mutual effects between drug metabolism and diseases, implications in precision medicine, and therapeutic development. Pharmaceutical scientists, drug metabolism researchers, and research physicians will benefit from the expert insights provided.
1. Chapter 1. Introduction of drug metabolism and overview of disease effect on drug metabolism - p. 1 2. Chapter 2. Regulation of drug metabolizing enzymes by inflammation - p. 27 3. Chapter 3. Regulation of drug transporters by inflammation - p. 63 4. Chapter 4. Drug metabolism in liver transplant patients - p. 103 5. Chapter 5. Drug metabolism in kidney disease - p. 139 6. Chapter 6. Drug and fatty acid cytochrome P450 metabolism in critical care - p. 169 7. Chapter 7. Drug metabolism in cardiovascular disease - p. 207 8. Chapter 8. Pharmacogenetic factors that affect drug metabolism and efficacy in type 2 diabetes mellitus - p. 229 9. Chapter 9. Drug metabolism in persons with human immunodeficiency virus - p. 261 10. Chapter 10. Drug metabolism in cancer patients - p. 287 11. Chapter 11. Hepatic drug metabolism in pediatric patients - p. 331 12. Age classification standards used in this chapter - p. 331 13. Reconciliation statement - p. 331 14. Introduction to pediatric hepatic drug metabolism - p. 332 15. Ontogeny of intrinsic clearance and liver size - p. 338 16. CYP450 and UGT enzyme families - p. 340 17. The gut microbiome in pediatric hepatic drug metabolism: Emerging mechanisms - p. 364 18. Development of alternative elimination pathways - p. 374 19. Clinical probe substrates for pediatric drug metabolism assessment - p. 377 20. Ontogeny of hepatic drug transporters - p. 383 21. Pediatric NAFLD and liver disease - p. 391 22. Special populations - p. 396 23. Summary - p. 405 24. Abbreviations - p. 406 25. Chapter 12. Drug metabolism in geriatric patients - p. 435 26. Chapter 13. Drug metabolism in pregnancy - p. 449 27. Chapter 14. Developmental regulation of drug metabolism and disposition - p. 495 28. Chapter 15. Gut microbiota impact on drug metabolism, bioavailability, and biotransformation - p. 515 29. Chapter 16. Circadian regulation of drug metabolism - p. 541 30. Chapter 17. Xenobiotic receptors in the cross-talk between drug metabolism and energy metabolism - p. 569 31. Chapter 18. Estrogen sulfotransferase (EST/SULT1E1) in mediating the mutual effect between drug metabolism and diseases, a case study - p. 599 32. Index - p. 629
Drug Metabolism in Diseases: Leveraging Drug Metabolism and Disposition in Precision Medicine and Therapeutic Development, Second Edition provides essential knowledge for pharmaceutical scientists and biologists to understand the interplay between diseases and physiological conditions, impacting drug metabolism and its implications in personalized treatment. Expanded with six new chapters since the first edition, this updated book covers the latest scientific findings. Other important points include the book’s comprehensive reference on mutual effects between drug metabolism and diseases, implications in precision medicine, and therapeutic development. Pharmaceutical scientists, drug metabolism researchers, and research physicians will benefit from the expert insights provided.
1. Chapter 1. Introduction of drug metabolism and overview of disease effect on drug metabolism - p. 1 2. Chapter 2. Regulation of drug metabolizing enzymes by inflammation - p. 27 3. Chapter 3. Regulation of drug transporters by inflammation - p. 63 4. Chapter 4. Drug metabolism in liver transplant patients - p. 103 5. Chapter 5. Drug metabolism in kidney disease - p. 139 6. Chapter 6. Drug and fatty acid cytochrome P450 metabolism in critical care - p. 169 7. Chapter 7. Drug metabolism in cardiovascular disease - p. 207 8. Chapter 8. Pharmacogenetic factors that affect drug metabolism and efficacy in type 2 diabetes mellitus - p. 229 9. Chapter 9. Drug metabolism in persons with human immunodeficiency virus - p. 261 10. Chapter 10. Drug metabolism in cancer patients - p. 287 11. Chapter 11. Hepatic drug metabolism in pediatric patients - p. 331 12. Age classification standards used in this chapter - p. 331 13. Reconciliation statement - p. 331 14. Introduction to pediatric hepatic drug metabolism - p. 332 15. Ontogeny of intrinsic clearance and liver size - p. 338 16. CYP450 and UGT enzyme families - p. 340 17. The gut microbiome in pediatric hepatic drug metabolism: Emerging mechanisms - p. 364 18. Development of alternative elimination pathways - p. 374 19. Clinical probe substrates for pediatric drug metabolism assessment - p. 377 20. Ontogeny of hepatic drug transporters - p. 383 21. Pediatric NAFLD and liver disease - p. 391 22. Special populations - p. 396 23. Summary - p. 405 24. Abbreviations - p. 406 25. Chapter 12. Drug metabolism in geriatric patients - p. 435 26. Chapter 13. Drug metabolism in pregnancy - p. 449 27. Chapter 14. Developmental regulation of drug metabolism and disposition - p. 495 28. Chapter 15. Gut microbiota impact on drug metabolism, bioavailability, and biotransformation - p. 515 29. Chapter 16. Circadian regulation of drug metabolism - p. 541 30. Chapter 17. Xenobiotic receptors in the cross-talk between drug metabolism and energy metabolism - p. 569 31. Chapter 18. Estrogen sulfotransferase (EST/SULT1E1) in mediating the mutual effect between drug metabolism and diseases, a case study - p. 599 32. Index - p. 629
